A RANDOMIZED TRIAL COMPARING PREOPERATIVE CHEMOTHERAPY PLUS SURGERY WITH SURGERY ALONE IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER
A RANDOMIZED TRIAL COMPARING PREOPERATIVE CHEMOTHERAPY PLUS SURGERY WITH SURGERY ALONE IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER
复制标题
DOI：
10.1056/nejm199401203300301
复制
发表时间：
1994-01-20
影响因子：
158.5
通讯作者：
ABAD, A
中科院分区：
文献类型：
--
作者：
ROSELL, R;GOMEZCODINA, J;ABAD, A
背景。手术对非小细胞肺癌患者的疗效有限，尽管最近的研究表明术前化疗可能提高生存率。我们进行了一项随机试验，以检查术前化疗和手术治疗非小细胞肺癌患者的可能益处。我们研究了60例IIIA期非小细胞肺癌患者（59男1女）。患者被随机分配接受单独手术或三个疗程的化疗（每平方米体表面积6毫克丝裂霉素，每平方米异环磷酰胺3克，每平方米50毫克顺铂），每隔三周静脉注射，然后进行手术。所有患者术后均接受纵隔放射治疗。采用K-ras癌基因分析和流式细胞术对切除肿瘤进行评价。化疗加手术患者的中位生存期为26个月，而单纯手术患者的中位生存期为8个月(P
Background. The efficacy of surgery for patients with non-small-cell lung cancer is limited, although recent studies suggest that preoperative chemotherapy may improve survival. We conducted a randomized trial to examine the possible benefit of preoperative chemotherapy and surgery for the treatment of patients with non-small-cell lung cancer.Methods. We studied 60 patients (59 men and 1 woman) with stage IIIA non-small-cell lung cancer. The patients were randomly assigned to receive either surgery alone or three courses of chemotherapy (6 mg of mitomycin per square meter of body-surface area, 3 g of ifosfamide per square meter, and 50 mg of cisplatin per square meter) given intravenously at three-week intervals and followed by surgery. All patients received mediastinal radiation after surgery. The resected tumors were evaluated by means of K-ras oncogene analysis and flow cytometry.Results. The median period of survival was 26 months in the patients with chemotherapy plus surgery, as compared with 8 months in the patients treated with surgery alone (P